Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,816 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.
Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann PJ, Kawaoka Y. Imai M, et al. Among authors: maeda k. N Engl J Med. 2023 Jan 5;388(1):89-91. doi: 10.1056/NEJMc2214302. Epub 2022 Dec 7. N Engl J Med. 2023. PMID: 36476720 Free PMC article. No abstract available.
Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval.
Miyamoto S, Kuroda Y, Kanno T, Ueno A, Shiwa-Sudo N, Iwata-Yoshikawa N, Sakai Y, Nagata N, Arashiro T, Ainai A, Moriyama S, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Fukushi S, Takahashi Y, Maeda K, Suzuki T. Miyamoto S, et al. Among authors: maeda k. iScience. 2023 May 19;26(5):106694. doi: 10.1016/j.isci.2023.106694. Epub 2023 Apr 19. iScience. 2023. PMID: 37124417 Free PMC article.
Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Fukushi S, Watanabe S, Suzuki T, Kikuchi T, Yotsuyanagi H, Maeda K, Kawaoka Y. Uraki R, et al. Among authors: maeda k. iScience. 2023 Oct 4;26(11):108147. doi: 10.1016/j.isci.2023.108147. eCollection 2023 Nov 17. iScience. 2023. PMID: 37876803 Free PMC article.
Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.
Watanabe S, Yoshikawa T, Kaku Y, Kurosu T, Fukushi S, Sugimoto S, Nishisaka Y, Fuji H, Marsh G, Maeda K, Ebihara H, Morikawa S, Shimojima M, Saijo M. Watanabe S, et al. Among authors: maeda k. PLoS Negl Trop Dis. 2023 Dec 15;17(12):e0011851. doi: 10.1371/journal.pntd.0011851. eCollection 2023 Dec. PLoS Negl Trop Dis. 2023. PMID: 38100536 Free PMC article.
Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults.
Morino E, Mine S, Tomita N, Uemura Y, Shimizu Y, Saito S, Suzuki T, Okumura N, Iwasaki H, Terada J, Ainai A, Sakai Y, Park E, Seki S, Akazawa D, Shimojima M, Shiwa-Sudo N, Virhuez-Mendoza M, Miyauchi K, Moriyama S, Iwata-Yoshikawa N, Harada M, Harada S, Hishiki T, Kotaki R, Matsumura T, Miyamoto S, Kanno T, Isogawa M, Watashi K, Nagata N, Ebihara H, Takahashi Y, Maeda K, Matano T, Wakita T, Suzuki T, Sugiura W, Ohmagari N, Ujiie M. Morino E, et al. Among authors: maeda k. NEJM Evid. 2024 Mar;3(3):EVIDoa2300290. doi: 10.1056/EVIDoa2300290. Epub 2024 Feb 27. NEJM Evid. 2024. PMID: 38411447
Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents.
Hishiki T, Morita T, Akazawa D, Ohashi H, Park ES, Kataoka M, Mifune J, Shionoya K, Tsuchimoto K, Ojima S, Azam AH, Nakajima S, Kawahara M, Yoshikawa T, Shimojima M, Kiga K, Maeda K, Suzuki T, Ebihara H, Takahashi Y, Watashi K. Hishiki T, et al. Among authors: maeda k. Microbiol Spectr. 2023 Aug 17;11(4):e0056623. doi: 10.1128/spectrum.00566-23. Epub 2023 Jul 6. Microbiol Spectr. 2023. PMID: 37409948 Free PMC article.
5,816 results